tHEORetically Speaking
Menu Close
  • Home
  • Guest Authors
  • About Us
  • HealthEconomics.Com
  • HE Jobs Portal

QALY

0

CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America

Posted on September 25, 2018 by Patti Peeples, R.Ph., Ph.D.

Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, CVS Caremark announced in August that it would allow self-funded insurers to exclude from their plan any drug launched at… Continue Reading →

cost-effectiveness, cost-effectiveness analysis, CVS Caremark, HealthEconomics.Com, HEOR, ICER, PBM, pharmaceutical, Pharmaceutical Pricing, Pharmacy Benefit Manager Catherine Stevenson, cost-effectiveness analysis, CVS Caremark, drug pricing, HealthEconomics.Com, ICER, patti peeples, PBM, QALY, value-based pricing

About the HealthEconomics.Com Blog:

Insights, observations, executive interviews, critical analysis, and new research for health economics, outcomes research, real-world evidence, and market access community. We welcome guest bloggers.

Check your inbox or spam folder to confirm your subscription.

Recent Posts

  • Podcast Q&A: The Benefits of Linking SDOH with Other Real-World Data
  • How Quality Research Initiatives are Advancing Precision Oncology and Value-Based Care
  • Podcast Q&A: Improving the Representativeness of Research
  • Podcast Q&A: Literature Reviews and Global Value Dossiers

HealthEconomics.Com Twitter Feed

www_healthecon Follow

@ ·
now

Reply on Twitter Retweet on Twitter Like on Twitter Twitter
Load More...

Archives

Visit our website, HealthEconomics.Com, top ranked by Google for news, jobs and resources in healthcare value, market access and more. Read our privacy policy here.
© 2023 tHEORetically Speaking. All rights reserved.
Hiero by aThemes